Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Analysis of biomarkers in the diagnostic of bladder cancer recurrence

Funder: São Paulo Research Foundation

Funding period
0
Funding amount
Abstract
Introduction: Bladder cancer is the forth most common neoplasia among men and is associated with a high recurrence chance, up to 70% in five years. Moreover, this tumor has a high mortality rate, between 30 and 70% according to the disease stage. Therefore, the follow-up for bladder cancer must be strict and continuous, comprising expensive and invasive exams. Because of this intense regimen of follow-up and the need for aggressive treatments, this tumor is one of the most expensive neoplasias to treat. Thus, it would be valuable to develop a new monitoring exam, less invasive and cheaper, that also could spare the patients from the inconvenient of invasive exams. In this way, efforts are being made to develop an efficient urine biomarker that could predict recurrence and prognosis of patients affected by bladder cancer. In the present study, we aim to evaluate the association between the secretion of eight different proteins in the urine of patients on follow-up for bladder cancer and the chance of tumor recurrence.Patients and Methods: Two hundred patients previously treated of bladder cancer and currently on follow-up regimen will be included. The subjects of this research will be selected from the ambulatory of the "Instituto do Câncer do Estado de São Paulo". Their urine will be collected during an ambulatory visit and send to be analyzed by ELISA. Primary endpoint is the correlation of eight proteins (MMP-9*, IL-8*, PAI-1*, APOA4*, coronin-1A, seminogelin-2, ³-synuclein and DJ-1) quantitative excretion in the urine and the chance of bladder cancer recurrence. Secondary endpoints are the association between eight proteins quantitative excretion in the urine with prognosis and anticipatory role for tumor recurrence. Minimal follow-up will be 2 years. A control group will comprise 50 healthy individuals, free from urological disorders or other known tumors. (AU)
Similar projects All >
Sorted by: Start Date
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science